Atria Investments LLC Takes Position in Insulet Co. (NASDAQ:PODD)

Atria Investments LLC bought a new stake in Insulet Co. (NASDAQ:PODDGet Rating) in the 1st quarter, HoldingsChannel.com reports. The firm bought 4,142 shares of the medical instruments supplier’s stock, valued at approximately $1,103,000.

Several other large investors have also modified their holdings of PODD. Pinebridge Investments L.P. acquired a new stake in Insulet during the 4th quarter worth $27,000. Confluence Wealth Services Inc. acquired a new stake in Insulet during the 4th quarter worth $28,000. Desjardins Global Asset Management Inc. acquired a new stake in Insulet during the 4th quarter worth $57,000. Leverty Financial Group LLC acquired a new stake in Insulet during the 4th quarter worth $62,000. Finally, GPS Wealth Strategies Group LLC boosted its stake in Insulet by 45.5% during the 1st quarter. GPS Wealth Strategies Group LLC now owns 240 shares of the medical instruments supplier’s stock worth $64,000 after purchasing an additional 75 shares during the period.

Insider Transactions at Insulet

In related news, COO Charles Alpuche sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $215.32, for a total value of $1,291,920.00. Following the sale, the chief operating officer now owns 43,899 shares of the company’s stock, valued at approximately $9,452,332.68. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, Director Shacey Petrovic sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $222.90, for a total value of $3,343,500.00. Following the sale, the director now owns 13,695 shares of the company’s stock, valued at approximately $3,052,615.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Charles Alpuche sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $215.32, for a total value of $1,291,920.00. Following the completion of the sale, the chief operating officer now directly owns 43,899 shares in the company, valued at approximately $9,452,332.68. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $243.61 on Thursday. The business’s 50 day simple moving average is $221.42 and its 200-day simple moving average is $235.15. The firm has a market capitalization of $16.89 billion, a price-to-earnings ratio of 386.69 and a beta of 0.70. The company has a debt-to-equity ratio of 3.11, a current ratio of 5.98 and a quick ratio of 4.51. Insulet Co. has a 12 month low of $181.00 and a 12 month high of $324.81.

Insulet (NASDAQ:PODDGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The medical instruments supplier reported $0.40 EPS for the quarter, topping the consensus estimate of $0.23 by $0.17. The business had revenue of $295.40 million for the quarter, compared to analyst estimates of $287.99 million. Insulet had a return on equity of 15.81% and a net margin of 3.91%. The company’s revenue for the quarter was up 17.1% compared to the same quarter last year. As a group, equities analysts forecast that Insulet Co. will post 1.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

PODD has been the subject of a number of recent research reports. StockNews.com initiated coverage on shares of Insulet in a research note on Thursday, March 31st. They set a “hold” rating for the company. Citigroup lowered shares of Insulet from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $310.00 to $250.00 in a research note on Monday, July 11th. Wells Fargo & Company reduced their price objective on shares of Insulet from $357.00 to $345.00 in a research report on Friday, May 6th. BTIG Research lowered their price objective on Insulet from $310.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, June 24th. Finally, Morgan Stanley lowered their price objective on Insulet from $268.00 to $244.00 and set an “equal weight” rating on the stock in a report on Tuesday, June 7th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $286.73.

Insulet Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Featured Stories

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDGet Rating).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.